Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain.
|
| Abstract | OBJECTIVE: Describe the consequences of dextropropoxyphene (DXP) market withdrawal on analgesic prescriptions and on the quality of therapeutic management of chronic pain. PATIENTS AND METHODS: From a cohort of non-institutionalised elderly patients with chronic pain recruited by general practitioners, we selected patients who were treated with DXP daily for at least 6 months just prior to DXP market withdrawal and who had an evaluation of pain and its impact on daily activities before and after DXP withdrawal. RESULTS: One hundred three patients took DXP daily for chronic pain. Immediately after DXP market withdrawal, 42 (40.8%), 55 (53.4%) and 3 (2.9%) patients were treated with step 1, 2 and 3 analgesics, respectively, and 3 patients (2.9%) were no longer receiving any analgesic medication. Among the 55 patients who continued on step 2 analgesics, 37 were treated with tramadol, 14 with codeine and 9 with opium. Pain intensity and the impact of pain on daily activities remained stable. CONCLUSION: DXP market withdrawal had no consequences on the intensity or impact of chronic pain in elderly patients.
|
|---|---|
| Authors | Laurent Becquemont, Tiba Delespierre, Bernard Bauduceau, Linda Benattar-Zibi, Gilles Berrut, Emmanuelle Corruble, Nicolas Danchin, Geneviève Derumeaux, Jean Doucet, Bruno Falissard, Francoise Forette, Olivier Hanon, Florence Pasquier, Michel Pinget, Rissane Ourabah, Sophie Bucher, Aida Lazkani, Celine Piedvache, Philippe Bertin |
| Journal | European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 70 Issue 10 Pg. 1237-42 (Oct 2014) ISSN: 1432-1041 [Electronic] Germany |
| PMID | 25066451 (Publication Type: Journal Article, Multicenter Study) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!